Compositions and method of administering tubulin binding agents for the treatment of ocular diseases

A technology of tubulin and binding agent, which is applied in the direction of drug combination, antiviral agent, medical preparation containing active ingredients, etc.

Inactive Publication Date: 2004-09-08
OXIGENE
View PDF24 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Additionally, delivering drugs to the eye...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and method of administering tubulin binding agents for the treatment of ocular diseases
  • Compositions and method of administering tubulin binding agents for the treatment of ocular diseases
  • Compositions and method of administering tubulin binding agents for the treatment of ocular diseases

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0114] Example 1. Topical administration with three routes of administration, study

[0115] Eye Irritation and Determination of Average Tolerance of CA4P

[0116] (i) Intravitreal medication

[0117] After intravitreal injection in rats, the test article CA4P was evaluated for possible intraocular irritation. After general anesthesia, 0.2 ml dose of CA4P was administered to the right eyes of 8 mice. Then, 0.2 ml dose of 0.9% sodium chloride USP solution was administered to the left eye of the rat as a negative control. Four different concentrations of CA4P were measured. Each of 4 concentrations (0.1 mg / ml, 1 mg / ml, 10 mg / ml, 100 mg / ml) was administered to the right eyes of 2 mice. Approximately 48 hours after administration, the eye was examined with a biomicroscopy slit lamp and an indirect ophthalmoscope. After recording the results, the experimental mice were euthanized. Immediately after euthanasia, a sample of the vitreous humor was aspirated and the number of...

example 2

[0129] Example 2. When using different routes of administration for topical administration in the eye

[0130] Evaluation of the in vivo distribution of CA4P

[0131] To effectively treat ocular neovascularization, extrasystemic drug delivery must pass through the relevant ocular structures to deliver effective doses of the drug to the diseased site. In order to confirm that different extrasystemic injections can produce effective distribution of CA4P in vivo, radioactive isotope tracer drug experiments were carried out.

[0132] method:

[0133] Unless stated below, each in vivo distribution experiment followed the protocol described below.

[0134] Will 14 C-CA4P (OxiGENE Inc. Watertown, MA) was suspended in 100 μl of saline solution, and then injected into anesthetized male New Zealand rats (4 months old, 1.8-2.5 kg, 3 vials per sample) with a 30G injection needle in the right eye. Corresponding to the use of 1, 5 and 5 μCi radioactive reagents, respectively, to de...

example 3

[0158] Example 3 adopts iontophoresis eye drug CA4P

[0159] CA4P can be ionized at physiological pH conditions, so it can be delivered by iontophoresis. Iontophoresis delivery (transcleral) of CA4P (10 mg / ml) was evaluated using the Vision Rabbit Eye Applicator (IOMED Inc, Salt Lake City, UT), which consisted of a 180 μl silicone container body. , connecting wires, and a monolayer hydrogel-impregnated polyvinyl acetal matrix, the 180 μl silicone container body is supported by a silver foil current distribution assembly covered with silver chloride. The contact surface area of ​​the applicator was 0.54 square centimeters. It was placed in the blind canal above the sclera of the right eye of New Zealand white rats (3-3.5 kg, n=6 per treatment), 1-2 mm above the edge of the distal front of the corneal-scleral junction. Adopt trademark Phoresor II TM A PM700 (IOMED Inc. Salt Lake City, UT) power supply, using 2, 3, and 4 mA of each applicator, was subjected to DC anodic ion...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Viscosityaaaaaaaaaa
Login to view more

Abstract

The present invention relates to the use of blood vessel target agent, especially tubulin binding agent, to treat diseases such as eye angiogenesis, eye tumor, diabetic retinopathy, premature retinopathy, retinoblastoma and macular degeneration.

Description

field of invention [0001] The present invention relates to the use of vascular targeting agents, particularly tubulin binding agents, for the treatment of ocular diseases. Background of the invention [0002] Eyes are one of the most important organs in life. The ability to maintain eye health is paramount due to age, disease, and other factors that impair vision. The main cause of blindness is the inability to introduce drugs or therapeutic agents into the eye and maintain an effective concentration of the drug or therapeutic agent in the eye. The drug is delivered systemically by oral administration of the drug, or by injection outside the eye. However, especially for the eye, systemic administration does not yield effective drug levels and, therefore, often requires administration at unacceptably high concentrations in order to achieve effective intraocular concentrations. [0003] The macula is an area of ​​the retina that contains a high concentration of photorecepto...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/06A61K9/08A61K31/09A61K31/135A61K45/00A61P3/10A61P9/00A61P9/10A61P27/02A61P35/00A61P43/00
CPCA61K31/135A61P3/10A61P9/00A61P9/10A61P17/02A61P27/02A61P31/04A61P31/12A61P35/00A61P43/00Y02A50/30A61K31/09
Inventor 戴维·谢里斯马克·伍德
Owner OXIGENE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap